Physician profile
Tara James
NPI 1518433804
$1,533.56
in general payments reported to CMS, 2019-2025
20 companies · $262 in 2025
The $262 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $262 · 2022: $305 · 2023: $465 · 2024: $239 · 2025: $262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $966.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $966.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $447.42 | 2021-2025 | Wegovy |
| Lilly USA, LLC | $232.86 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $204.02 | 2023-2025 | Farxiga, Breztri |
| Amgen INC. | $136.45 | 2023-2025 | Repatha, Otezla, Otezla |
| Abbvie INC. | $103.85 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $96.63 | 2021 | |
| Eisai INC. | $43.21 | 2021-2025 | |
| Exact Sciences Corporation | $37.59 | 2025 | The Cologuard Plus Collection Kit |
| Atricure, INC. | $37.06 | 2023-2024 | |
| Smith+Nephew, INC. | $25.00 | 2024 | Grafix Pl |
| Clarus Therapeutics INC. | $24.23 | 2021 | |
| Medtronic, INC. | $18.71 | 2025 | Intellis Adaptivestim |
| Pfizer INC. | $18.47 | 2022 | |
| Paratek Pharmaceuticals, INC. | $16.98 | 2025 | Nuzyra |
| Novartis Pharmaceuticals Corporation | $16.23 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $16.03 | 2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $15.64 | 2022 | |
| Tolmar, INC. | $14.98 | 2024 | |
| Daiichi Sankyo INC. | $14.55 | 2023 | Injectafer |
| Glaxosmithkline, LLC. | $13.65 | 2023 | Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tara James listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.